New insights into the burden and costs of multiple sclerosis in Europe
Tóm tắt
The current focus in multiple sclerosis (MS) is on early diagnosis and drug intervention, with a view to modifying disease progression. Consequently, healthcare costs have shifted from inpatient care and rehabilitation to outpatient care.
This European burden of illness study provides data that can be combined with other evidence to assess whether management approaches provide value to society.
A cross-sectional study was conducted in 16 countries. Patients reported on their disease, health-related quality of life (HRQoL) and resource consumption. Descriptive analyses were performed by disease severity. Costs are reported from a societal perspective in 2015€ PPP (adjusted for purchasing power parity).
The 16,808 participants had a mean age of 51.5 years, and 52% had relapsing–remitting multiple sclerosis (RRMS). Work capacity declined from 82% to 8%, and utility declined from normal population values to less than zero with advancing disease. Mean costs were 22,800€ PPP in mild, 37,100€ PPP in moderate and 57,500€ PPP in severe disease; healthcare accounted for 68%, 47% and 26%, respectively. Fatigue and cognitive difficulties were reported by 95% and 71% of participants, respectively; both had a significant independent effect on utility.
Costs and utility were highly correlated with disease severity, but resource consumption was heavily influenced by healthcare systems organisation and availability of services.
Từ khóa
Tài liệu tham khảo
O’Brien B. Multiple sclerosis. London: Office of Health Economics, 1987, https://www.ohe.org/system/files/private/publications/162%20-%201987_Multiple_Sclerosis_OBrien.pdf?download=1 (accessed 5 October 2016).
Blumhardt L, 1996, Br J Med Econ, 10, 99
Kobelt G, Lindgren P, Parkin D, Costs and quality of life in multiple sclerosis: A cross-sectional observational study in the UK. EFI research report no. 398, 2000. Stockholm: Stockholm School of Economics, http://swopec.hhs.se/hastef/papers/hastef0398.pdf (accessed 5 October 2016).
Kobelt G, Kasteng F. Access to innovative treatments in multiple sclerosis in Europe. Brussels: The European Federation of Pharmaceutical Industry Associations (EFPIA), 2009, http://www.comparatorreports.se/Access%20to%20MS%20treatments%20-%20October%202009.pdf (accessed 5 October 2016).
Edling A, Stenberg AM. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Stockholm: Pharmaceutical Benefits Board, 2003, http://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf (accessed 5 October 2016).
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. National institute for Health and Care Excellence, 2013, https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (accessed 5 October 2016).
Radick L, 2015, Am Health Drug Benefits, 8, 448
Kobelt G., 2006, Int MS J, 13, 17
Dolan P, Gudex C, Kind P, A social tariff for EuroQol: Results from a UK general population survey (discussion paper number 138). York: Centre for Health Economics, University of York, 1995, http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20138.pdf (accessed 5 October 2016).
Paris V, Belloni A. Value in pharmaceutical pricing. OECD Publishing, 2013, http://apps.who.int/medicinedocs/documents/s21368en/s21368en.pdf (accessed 5 October 2016).
Fox RJ, 2015, Neurodegener Dis Manag, 5, 3